Takeda PharmaceuticalTAK
紐約證券 · USD
14.16
+0.44
(+3.21%)
收盤 08/02 03:59 (UTC+8)
盤後
14.11
14.11
(-0.35%)
08/02 03:59 (UTC+8)
Takeda PharmaceuticalTAK
14.16
+0.44
(+3.21%)
財務數據
損益表
- 10965.51
- 9561.56
- 10586.18
- 10430.89
- 11111.86
- 10508.69
- 12079.90
- 11760.38
- 11441.24
- 10533.99
- 9.40
- -12.80
- 10.72
- -1.47
- 6.53
- -5.43
- 14.95
- -2.65
- -2.71
- -7.93
- 營業收入(億)
- 季增長率(%)
單位：美元千元
2025/Q1 | 2024/Q4 | 2024/Q3 | 2024/Q2 | 2024/Q1 | 2023/Q4 | 2023/Q3 | 2023/Q2 | 2023/Q1 | 2022/Q4 | |
營業收入淨額 | 1,053,399,000 | 1,144,124,000 | 1,176,038,000 | 1,207,990,000 | 1,050,869,000 | 1,111,186,000 | 1,043,089,000 | 1,058,618,000 | 956,156,000 | 1,096,551,000 |
營業成本 | 382,078,000 | 416,874,000 | 394,311,000 | 386,954,000 | 382,501,000 | 379,481,000 | 343,582,000 | 321,114,000 | 309,772,000 | 335,973,000 |
營業毛利 | 671,321,000 | 727,250,000 | 781,727,000 | 821,036,000 | 668,368,000 | 731,705,000 | 699,507,000 | 737,504,000 | 646,384,000 | 760,578,000 |
營業費用 | 602,778,000 | 749,698,000 | 508,089,000 | 654,708,000 | 571,558,000 | 677,037,000 | 748,849,000 | 568,933,000 | 495,220,000 | 613,588,000 |
研發費用 | 216,007,000 | 170,193,000 | 175,564,000 | 168,463,000 | 195,856,000 | 187,381,000 | 183,946,000 | 162,741,000 | 160,944,000 | 174,629,000 |
推銷及管理費用 | 295,866,000 | 270,588,000 | 268,282,000 | 270,030,000 | 285,234,000 | 267,520,000 | 252,952,000 | 248,113,000 | 254,796,000 | 262,299,000 |
非經常性項目費用 | - | - | - | - | - | - | - | - | - | - |
其他營業費用 | -112,170,000 | 146,242,000 | -50,409,000 | 53,384,000 | -54,646,000 | 84,798,000 | 71,709,000 | 28,656,000 | -53,744,000 | 41,084,000 |
營業利益 | 68,543,000 | -22,448,000 | 273,638,000 | 166,328,000 | 96,810,000 | 54,668,000 | -49,342,000 | 168,571,000 | 151,164,000 | 146,990,000 |
其他收入及費用 | - | - | - | - | - | - | - | - | - | - |
利息費用 | -22,430,000 | 31,596,000 | 68,454,000 | 59,691,000 | -53,128,000 | 66,568,000 | 58,022,000 | 59,575,000 | -9,792,000 | 79,749,000 |
稅前純益 | -107,299,000 | 26,407,000 | 119,372,000 | 136,604,000 | -47,522,000 | 61,260,000 | -95,980,000 | 135,033,000 | 47,915,000 | 107,153,000 |
所得稅 | -4,201,000 | 2,572,000 | 27,266,000 | 41,304,000 | -44,528,000 | -44,496,000 | -48,009,000 | 45,627,000 | 16,779,000 | -11,996,000 |
稅後純益 | -103,155,000 | 23,789,000 | 92,046,000 | 95,248,000 | -3,018,000 | 105,720,000 | -48,030,000 | 89,395,000 | 31,134,000 | 119,127,000 |
基本每股稅後盈餘(元) | - | - | - | 30.36 | - | - | -15.34 | 28.76 | 9.99 | 38.32 |
稀釋每股稅後盈餘(元) | - | - | - | 29.97 | - | - | -15.34 | 28.56 | 9.65 | 37.93 |
基本平均股數(千股) | - | - | - | 3137830.00 | - | - | 3130592.00 | 3108838.00 | 3108520.00 | 3109048.00 |
稀釋平均股數(千股) | - | - | - | 3178111.00 | - | - | 3130592.00 | 3130077.00 | 3167566.00 | 3140832.00 |
還原基本每股稅後盈餘(元) | - | - | - | 30.36 | - | - | -15.34 | 28.76 | 9.99 | 38.32 |
還原稀釋每股稅後盈餘(元) | - | - | - | 29.97 | - | - | -15.34 | 28.56 | 9.65 | 37.93 |
還原基本平均股數(千股) | - | - | - | 3,137,830 | - | - | 3,130,592 | 3,108,838 | 3,108,520 | 3,109,048 |
還原稀釋平均股數(千股) | - | - | - | 3,178,111 | - | - | 3,130,592 | 3,130,077 | 3,167,566 | 3,140,832 |
EBITDA(千元) | 59,983,000 | 244,912,000 | 380,218,000 | 388,463,000 | 86,070,000 | 314,853,000 | 144,679,000 | 366,098,000 | 199,531,000 | 363,760,000 |